Literature DB >> 23335117

Validation of an algorithm to estimate gestational age in electronic health plan databases.

Qian Li1, Susan E Andrade, William O Cooper, Robert L Davis, Sascha Dublin, Tarek A Hammad, Pamala A Pawloski, Simone P Pinheiro, Marsha A Raebel, Pamela E Scott, David H Smith, Inna Dashevsky, Katherine Haffenreffer, Karin E Johnson, Sengwee Toh.   

Abstract

PURPOSE: To validate an algorithm that uses delivery date and diagnosis codes to define gestational age at birth in electronic health plan databases.
METHODS: Using data from 225,384 live born deliveries to women aged 15-45 years in 2001-2007 within eight of the 11 health plans participating in the Medication Exposure in Pregnancy Risk Evaluation Program, we compared (1) the algorithm-derived gestational age versus the "gold-standard" gestational age obtained from the infant birth certificate file and (2) the prenatal exposure status of two antidepressants (fluoxetine and sertraline) and two antibiotics (amoxicillin and azithromycin) as determined by the algorithm-derived versus the gold-standard gestational age.
RESULTS: The mean algorithm-derived gestational age at birth was lower than the mean obtained from the birth certificate file among singleton deliveries (267.9 vs 273.5 days) but not among multiple-gestation deliveries (253.9 vs 252.6 days). The algorithm-derived prenatal exposure to the antidepressants had a sensitivity and a positive predictive value of ≥95%, and a specificity and a negative predictive value of almost 100%. Sensitivity and positive predictive value were both ≥90%, and specificity and negative predictive value were both >99% for the antibiotics.
CONCLUSIONS: A gestational age algorithm based upon electronic health plan data correctly classified medication exposure status in most live born deliveries, but trimester-specific misclassification may be higher for drugs typically used for short durations.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335117      PMCID: PMC3644383          DOI: 10.1002/pds.3407

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  27 in total

1.  Folic acid antagonists during pregnancy and the risk of birth defects.

Authors:  S Hernández-Díaz; M M Werler; A M Walker; A A Mitchell
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

2.  Cessation of asthma medication in early pregnancy.

Authors:  Rachel Enriquez; Pingsheng Wu; Marie R Griffin; Tebeb Gebretsadik; Ayumi Shintani; Ed Mitchel; Kecia N Carroll; Tina V Hartert
Journal:  Am J Obstet Gynecol       Date:  2006-05-02       Impact factor: 8.661

3.  Comparison of two measures of gestational age among low income births. The potential impact on health studies, New York, 2005.

Authors:  Victoria Lazariu; Christopher F Davis; Louise-Anne McNutt
Journal:  Matern Child Health J       Date:  2013-01

4.  Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data.

Authors:  Marsha A Raebel; Jennifer L Ellis; Susan E Andrade
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-12       Impact factor: 2.890

5.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

Authors:  Carol Louik; Angela E Lin; Martha M Werler; Sonia Hernández-Díaz; Allen A Mitchell
Journal:  N Engl J Med       Date:  2007-06-28       Impact factor: 91.245

Review 6.  Gestational age estimation on United States livebirth certificates: a historical overview.

Authors:  Megan L Wier; Michelle Pearl; Martin Kharrazi
Journal:  Paediatr Perinat Epidemiol       Date:  2007-09       Impact factor: 3.980

7.  Discordance between LMP-based and clinically estimated gestational age: implications for research, programs, and policy.

Authors:  G R Alexander; M E Tompkins; D J Petersen; T C Hulsey; J Mor
Journal:  Public Health Rep       Date:  1995 Jul-Aug       Impact factor: 2.792

8.  Major congenital malformations after first-trimester exposure to ACE inhibitors.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon Dyer; Patricia S Gideon; Kathi Hall; Wayne A Ray
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

9.  Safety of medications prescribed before and during early pregnancy in a cohort of 81,975 mothers from the UK General Practice Research Database.

Authors:  Janet R Hardy; Brian P Leaderer; Theodore R Holford; Gillian C Hall; Michael B Bracken
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

10.  Use of prescription medications with a potential for fetal harm among pregnant women.

Authors:  Susan E Andrade; Marsha A Raebel; Abraham N Morse; Robert L Davis; K Arnold Chan; Jonathan A Finkelstein; Kris K Fortman; Heather McPhillips; Douglas Roblin; David H Smith; Marianne Ulcickas Yood; Richard Platt; Jerry H Gurwitz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-08       Impact factor: 2.890

View more
  30 in total

1.  Patterns of prescription of antidepressants and antipsychotics across and within pregnancies in a population-based UK cohort.

Authors:  Andrea V Margulis; Elizabeth M Kang; Tarek A Hammad
Journal:  Matern Child Health J       Date:  2014-09

2.  Prenatal Tdap immunization and risk of maternal and newborn adverse events.

Authors:  J Bradley Layton; Anne M Butler; Dongmei Li; Kim A Boggess; David J Weber; Leah J McGrath; Sylvia Becker-Dreps
Journal:  Vaccine       Date:  2017-06-29       Impact factor: 3.641

3.  Using insurance claims data to identify and estimate critical periods in pregnancy: An application to antidepressants.

Authors:  Elizabeth C Ailes; Regina M Simeone; April L Dawson; Emily E Petersen; Suzanne M Gilboa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2016-11

4.  Association of Maternal Use of Folic Acid and Multivitamin Supplements in the Periods Before and During Pregnancy With the Risk of Autism Spectrum Disorder in Offspring.

Authors:  Stephen Z Levine; Arad Kodesh; Alexander Viktorin; Lauren Smith; Rudolf Uher; Abraham Reichenberg; Sven Sandin
Journal:  JAMA Psychiatry       Date:  2018-02-01       Impact factor: 21.596

Review 5.  Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Authors:  Krista F Huybrechts; Brian T Bateman; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-10       Impact factor: 2.890

6.  Employer-Sponsored Plan Expenditures for Infants Born Preterm.

Authors:  Scott D Grosse; Norman J Waitzman; Ninee Yang; Karon Abe; Wanda D Barfield
Journal:  Pediatrics       Date:  2017-10       Impact factor: 7.124

7.  Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries.

Authors:  Sengwee Toh; Qian Li; T Craig Cheetham; William O Cooper; Robert L Davis; Sascha Dublin; Tarek A Hammad; De-Kun Li; Pamala A Pawloski; Simone P Pinheiro; Marsha A Raebel; Pamela E Scott; David H Smith; William V Bobo; Jean M Lawrence; Inna Dashevsky; Katherine Haffenreffer; Lyndsay A Avalos; Susan E Andrade
Journal:  Arch Womens Ment Health       Date:  2013-02-07       Impact factor: 3.633

8.  The prevalence and trends of antiviral medication use during pregnancy in the US: a population-based study of 664,297 deliveries in 2001-2007.

Authors:  Lyndsay A Avalos; Hong Chen; Chunmei Yang; Susan E Andrade; William O Cooper; Craig T Cheetham; Robert L Davis; Sascha Dublin; Tarek A Hammad; Sigal Kaplan; Pamala A Pawloski; Marsha A Raebel; Pamela E Scott; David H Smith; Sengwee Toh; De-Kun Li
Journal:  Matern Child Health J       Date:  2014-01

9.  Surveillance of Medication Use During Pregnancy in the Mini-Sentinel Program.

Authors:  Susan E Andrade; Sengwee Toh; Monika Houstoun; Katrina Mott; Marilyn Pitts; Caren Kieswetter; Carrie Ceresa; Katherine Haffenreffer; Marsha E Reichman
Journal:  Matern Child Health J       Date:  2016-04

10.  Selective serotonin reuptake inhibitor use patterns among commercially insured US pregnancies (2005-2014).

Authors:  Julie M Petersen; Daina B Esposito; Martha M Werler
Journal:  Arch Womens Ment Health       Date:  2020-03-28       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.